STOCK TITAN

Zomedica Corp - ZOM STOCK NEWS

Welcome to our dedicated news page for Zomedica (Ticker: ZOM), a resource for investors and traders seeking the latest updates and insights on Zomedica.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zomedica's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zomedica's position in the market.

Rhea-AI Summary
Zomedica Corp. (NYSE American:ZOM) reported consolidated financial results for Q3 2023, highlighting a 31% revenue growth to $6.3 million, driven by increased sales in Therapeutic Devices and Diagnostic segments. Gross margin reached 69%. The company ended the quarter with $118.0 million in cash. Non-GAAP EBITDA loss was $0.3 million compared to $3.0 million in Q3 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
-
Rhea-AI Summary
Zomedica Corp. will host a conference call and webcast on November 13, 2023, to discuss its operational and financial highlights for Q3 2023. The call will be followed by a question-and-answer session. Interested individuals can access the webcast and a dial-in replay of the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.23%
Tags
conferences earnings
-
Rhea-AI Summary
Zomedica Corp. to present at Lytham Partners Fall 2023 Investor Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.86%
Tags
-
Rhea-AI Summary
Zomedica Corp. to present at LD Micro Main Event XVI Conference on October 3rd. Larry Heaton, CEO, will give the presentation. The event will feature around 200 companies presenting and attending private meetings with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
conferences
-
Rhea-AI Summary
Zomedica Corp. announces commercial launch of eACTH assay for equine plasma on TRUFORMA platform, targeting equine veterinarians. Assay enables diagnosis of equine Cushing's Disease and monitoring of positive patients. Business opportunity to engage with Equine Veterinary community and reach millions of horses in the US susceptible to PPID.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
none
News
Rhea-AI Summary
Zomedica Corp. has received a notice from NYSE American stating that it is not in compliance with the listing standards due to low share price. The company plans to take measures to cure the deficiency and remain listed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
none
-
Rhea-AI Summary
Zomedica Corp. completes acquisition of Structured Monitoring Products, Inc. and plans to manufacture and distribute VetGuardian touchless vital signs monitoring technology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
-
Rhea-AI Summary
Zomedica Corp. CEO to provide strategic update at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Zomedica Corp. reports Q2 2023 financial results, with revenue of $6.0 million, a 43% increase compared to Q2 2022. Therapeutic segment revenue increased by 38% and diagnostic segment revenue doubled. Gross margin was 67%. Zomedica ended the quarter with $142.4 million in cash. The company expects revenue to continue increasing in subsequent periods.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.38%
Tags
Zomedica Corp

NYSE:ZOM

ZOM Rankings

ZOM Stock Data

132.29M
963.34M
1.59%
8.89%
6.53%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Ann Arbor

About ZOM

zomedica (nyse american:zom) (tsx-v:zom) is a veterinary diagnostic and pharmaceutical and company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. with a team that includes clinical veterinary professionals, it is zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care.